In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mitsubishi Tanabe Domestic Sales Grow 7 Percent

This article was originally published in PharmAsia News

Executive Summary

Mitsubishi Tanabe domestic sales from April to December grew 7.1 percent to ¥282.3 billion

You may also be interested in...



MHLW Suspends Mitsubishi Tanabe Operations For Fabricating Data

TOKYO - Japan's Ministry of Health, Labor and Welfare has suspended Mitsubishi Tanabe Pharma's manufacturing and sales operations for 25 days because it was determined a subsidiary of the company fabricated data for Medway Injection 5%, the world's first genetically engineered transgenic human serum albumin, MHLW officials said April 13, and regulatory authorities may level additional administrative penalties against the company

Virtual Clinical Trials Find Bigger Voice As COVID-19 Forces Pharma Rethink

The use of virtual, real-time and at-home testing to provide clinical trials data has been steadily gaining the interest of the health care industry. COVID-19 has put this opportunity into sharper focus, says CNS trials technology developer Cambridge Cognition, which is now adding a voice option to its portfolio.

Device/Diagnostics Quarterly Dealmaking Statistics, Q1 2020

Device financing totaled $1.4bn during the first quarter of 2020. Merger and acquisition activity reached $714.5m, with only two transactions hitting the six-figure mark. Financings by diagnostics/research players totaled $985m and just six companies were acquired, four of which together were valued at $11.6bn, most coming from Thermo Fisher Scientific’s $11.5bn buy of fellow public life sciences company Qiagen NV.

UsernamePublicRestriction

Register

SC142523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel